Skip to main
ONC
ONC logo

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 64%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines is poised for significant revenue growth, driven by the anticipated launches of zanidatamab and tarlatamab in China, alongside the continued performance of established products like Xgeva and Kyprolis. With expected strong sales of Brukinsa, projected at $936 million for the second quarter, and potential market expansion due to its leading position as the top BTK inhibitor, the company is well-positioned for sustained long-term success, with peak sales estimated at $7.1 billion. Additionally, the promising outlook for next-generation therapies like sonrotoclaxis further supports BeOne's growth trajectory, as these advancements could enhance revenue despite potential pricing challenges.

Bears say

BeOne Medicines faces several fundamental concerns that contribute to a negative outlook on its stock. The reliance on Brukinsa, which accounts for over 60% of revenue, coupled with slow uptake of commercial products and unsuccessful pipeline initiatives, raises doubts about the company’s ability to sustain growth amidst a crowded oncology market. Additionally, geopolitical risks and significant cash burn on R&D efforts without guaranteed returns further exacerbate the financial uncertainties surrounding BeOne's future performance.

BeiGene Ltd (ONC) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 64% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 11 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $374.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $374.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.